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Abstract
KRAS mutations are major factors involved in initiation and maintenance of pancreatic tumors. The impact of different
mutations on patient survival has not been clearly defined. We screened tumors from 171 pancreatic cancer patients for
mutations in KRAS and CDKN2A genes. Mutations in KRAS were detected in 134 tumors, with 131 in codon 12 and only 3 in
codon 61. The GGT.GAT (G12D) was the most frequent mutation and was present in 60% (80/134). Deletions and
mutations in CDKN2A were detected in 43 tumors. Analysis showed that KRAS mutations were associated with reduced
patient survival in both malignant exocrine and ductal adenocarcinomas (PDAC). Patients with PDACs that had KRAS
mutations showed a median survival of 17 months compared to 30 months for those without mutations (log-rank P= 0.07)
with a multivariate hazard ratio (HR) of 2.19 (95%CI 1.09–4.42). The patients with G12D mutation showed a median survival
of 16 months (log-rank-test P = 0.03) and an associated multivariate HR 2.42 (95%CI 1.14–2.67). Although, the association of
survival in PDAC patients with CDKN2A aberrations in tumors was not statistically significant, the sub-group of patients with
concomitant KRAS mutations and CDKN2A alterations in tumors were associated with a median survival of 13.5 months
compared to 22 months without mutation (log-rank-test P = 0.02) and a corresponding HR of 3.07 (95%CI 1.33–7.10). Our
results are indicative of an association between mutational status and survival in PDAC patients, which if confirmed in
subsequent studies can have potential clinical application.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the most fatal
form of pancreatic malignancy with a 5 year survival of less than
4% [1,2]. Tumor heterogeneity, lack of early detection methods
and refractoriness to conventional chemotherapy all contribute to
the poor outcome [2]. Surgical resection has limited potential for
cure, with less than 20% of patients eligible for surgery with
curative intent, due to local spread or metastasis [3]. PDAC is
thought to develop from PanIN lesions (pancreatic intraepithelial
neoplasia) through progressive accumulation of somatic alterations
in critical genes [4,5]. Despite a repertoire of information, studies
linking somatic alterations in PDAC with patient survival are
lacking.
Over the years somatic mutations have been shown to be
legitimate targets for anti-cancer drugs because of casual
relationship with tumor formation and maintenance [6]. Histo-
logical indistinct tumors, based on the mutational profiles are
reported to be differentially amenable to chemotherapeutics [7].
Specific chemotherapeutics, based on mutational status, in
colorectal, lung, melanoma and other cancer types are already
part of cancer treatments [8–12]. Despite KRAS being the most
frequently mutated oncogene in pancreatic cancer with a reported
frequency ranging between 20 and 100%, it has not been so far
utilized in categorization of tumors for clinical purposes [13].
Though, some previous reports have suggested association of
KRAS mutations in resected pancreatic cancers with prognosis
[14,15].
Most of the earlier reports on KRAS mutations in pancreatic
cancer were based on relatively small tumor numbers that lacked
statistical power to determine association with the disease
outcome. In order to address the issue of frequency of KRAS
mutation in pancreatic cancer and impact of those mutations on
disease outcome, we have in this study included a series of fully
characterized 171 pancreatic tumors with complete patient data.
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Results
The 163 patients with malignant tumors in this study comprised
the following: i) 143 ductal adenocarcinomas that also included 5
adenosquamous and 4 anaplastic undifferentiated variants, ii) 16
rare carcinomas that were comprised of 2 acinar cell carcinomas, 2
(microcystic) tubulo-papillary carcinomas, 9 intraductal papillary
mucinous neoplasm (IPMN, invasive type), 2 solid pseudopapillary
neoplasms (Frantz tumors) and 1 cystadenocarcinoma, and iii) 4
papillary (ampulla of Vater) carcinomas. The non-malignant
group was composed of 4 benign lesions in the form of serous
cystic adenomas (SCA) and premalignant lesions in the form of 1
mucinous cystic neoplasm (MCN) and 3 non-invasive IPMN
(Table 1 and Table S3). All patients except nine received standard
Gemcitabine treatment. Out of remaining nine patients, eight
received 5-fluorouracil/folinic acid and one patient received 5-
fluorouracil and interferon-alpha together with radiation therapy
(Table S3).
Mutation detection for KRAS gene was standardized using DNA
from cell lines with known KRAS mutation. The sensitivity of
SSCP, determined by titration experiments, showed that point
mutations in tumor samples up to 5% tumor content were
detectable. This provided confidence that our inclusion of tumor
samples, only if those had at least 10% tumor content (n = 171),
would more than adequately enable the detection of mutations.
Another criterion applied for mutation detection was reproduc-
ibility. Mutations were scored only when band shifts were
reproducible in at least two independent experiments. Repeat
experiments using SSCP followed by DNA sequencing were used
for confirmation and identification of mutations (Figure S2). We
also obtained independent confirmation of KRAS mutations in a
random sub-set (n = 6) analyzed blindly in the reference laboratory
of the Institute of Pathology, University Hospital of Heidelberg.
In the KRAS gene, we detected 134 mutations in 171 tumors
(78%), with 131 mutations in exon 2 and 3 mutations in exon 3
(Table 1). Mutations in exon 2 in all tumors were localized to
codon 12. Out of 131 tumors that carried mutation at codon 12,
61% tumors had GGT.GAT (G12D, 80 of 131) mutation,
followed by GGT.CGT (G12R, 23 of 131, 18%), GGT.GTT
(G12V, 22 of 131, 17%), GGT.TGT (G12C, 4 of 131, 3%),
GGT.GCT (G12A, 1 of 131) and GGT.GTC (G12V, 1 of 131).
Three tumors carried mutations in exon 3 that were confined to
codon 61 featuring the Q61H mutation due to CAA.CAC base
change. The mutation frequency in ductal adenocarcinomas was
82% (117 of 143) including adenosquamous and anaplastic
undifferentiated tumors. All 4 of the ampulla of Vater tumors
showed KRAS mutation, while 7 of 9 IPMN-malignant types
harbored mutation (Table 1 and Table S3).
A total of 43 tumors (25%) showed aberrations in the CDKN2A
gene. Of the CDKN2A alterations in 43 tumors, 9 carried point
mutations and the remainder showed deletion at the locus. All the
point mutations in the gene were located in exon 2. Two tumors
carried mutation at codon 80 (CGA.TGA, R80*), 3 at codon 83
(CAC.TAC, H83Y), followed by solitary tumors with mutations
at codon 58 (CGA.TGA, R58*), codon 129 (TAC.TAA,
Y129*), codon 130 (CTG.CAG, L130Q) and one tumor had 2
base pair insertion of GG at codon 78 (CTC.CGGTC). Deletions
at the 9p21 locus were detected with varying frequency with 17–
20% in the CDKN2A (p16INK4a) and 26–28% within the promoter
associated with exon 1b of p14ARF transcript.
Univariate analyses showed that among clinico-pathological
factors, only tumor grade significantly affected overall survival in
the studied cohort (Table 1). Presence of KRAS mutations tended
to shorten survival of patients in general (n = 150; P= 0.07) and in
all studied sub-categories (except tumor stage T4), however
without reaching statistical significance (Table S2). In 150 patients
with malignant exocrine tumors, the activating KRAS mutations
were associated with reduction in median survival time nearly by
half (17 vs 30 months, Kaplan-Meier method with log-rank test
P= 0.07; Figure S3A). The presence of KRAS mutations was
associated with poor survival in tumor stage III (HR=1.94,
P= 0.03; Table S2). Risk factors such as smoking, alcohol
consumption or diabetes had no effect on patient survival either
with or without KRAS mutations. A multivariate Cox regression
model that included age, gender, TNM, tumor grade and tumor
histology as co-variants confirmed KRAS mutational status as a
potential independent prognostic marker with a hazard ratio (HR)
of 1.87 (95%CI 0.99–3.51, P= 0.05; Table 2). Analysis with
specific types of KRAS mutations at codon 12 showed that the
G12D variant was associated with a median survival time of 16
months compared to 30 months for wildtype KRAS (log-rank test,
P = 0.02; Figure S3B) and HR of 1.99 (95%CI 1.02–3.90,
P= 0.05; multivariate cox-regression analysis; Table 2). Patients
with any CDKN2A aberration in tumors showed a shorter median
survival time of 13.5 months compared to 19 months in patients
without aberrations, however, the difference was not statistically
significant (log-rank P= 0.14). The corresponding HR was 1.55
(95%CI 0.97–2.48, P= 0.07; Table 2). The survival of patients
with concomitant KRAS mutations and CDKN2A aberrations
(n = 31) was poorest with median survival time of 13 months
compared to 30 months for patients without any mutations in
either KRAS or CDKN2A (log rank P= 0.03; Figure S3C). Out of 31
tumors with concomitant mutations in KRAS and CDKN2A, 30
were stage III or IV. Twenty three of those tumors were
lymphnode positive. The HR for the presence of concomitant
aberrations in both genes was 2.77 (95%CI 1.23–6.23, P = 0.01;
Table 2).
Analysis of survival only for PDAC patients (n = 128) showed a
similar association with KRAS mutational status. Patients with
KRAS mutations were associated with a median survival time of 17
months compared to 30 months for those without mutations (log-
rank test P= 0.07; Figure 1A). Multivariate Cox regression showed
association of KRAS mutations with a HR of 2.19 (95%CI 1.09–
4.42; Table 3). PDAC patients with G12D mutation in KRAS had
16 months of median survival (log rank P= 0.03; Figure 1B). And
the sub-group of PDAC patients with concomitant mutations in
KRAS and CDKN2A had a shortest survival of 13.5 months (log
rank test P= 0.02; Figure 1C) and a HR of 3.07 (95%CI 1.33–
7.10; Table 3).
Discussion
Mutations in KRAS and CDKN2A genes in pancreatic cancer are
well documented; however, their influence on disease outcome in
patients with exocrine pancreatic tumors has remained unclear. In
this study, we observed that KRAS mutation frequency in
pancreatic tumors was consistent with ours and other previous
European studies that were based on 70–100 tumors and reported
a mutation frequency of 72–83% [14,16,17]. Earlier, a Korean
study on paraffin embedded 136 tumors reported a mutation
frequency of 52% [18]. KRAS mutations in pancreatic cancer are
believed to be the early events in neoplastic transformation. The
hypothesis is supported by mice models based on conditional
endogenous expression of the mutant KRAS. Those mouse models
were developed with an assumption that KRAS mutation is an
essential and early somatic genetic alteration in PDAC progres-
sion. Similar observations were reported for KRAS mutations in
human acinar-ductal metaplasia (ADM) lesions of pancreas [19].
Somatic Mutations in Pancreatic Cancer
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Table 1. Clinical-pathological parameters of pancreatic cancer patients.





Months (95% CI) Log-rank P *
All categories 159 (93) 159 (45) 16 (9–26)
12 (6 no follow up; 6 deaths due to other causes)
Gender Male 100 (58) 92 (27) 19 (16–28) 0.19
Female 71 (42) 67 (18) 17 (11–22)
Age at surgery
(years)
Median= 65 (56–70); Mean = 63 6 11.31 171 159 (45) 16 (9–26) –
Histologic
variants
n= 171 n = 159 (45)
benign Serous cystadenoma, SCA 4 (2) 4 (4) – –
premalignant Mucinous cystic neoplasm, MCN 1 (1) 1 (1) – –
Intraductal papillary mucinous neoplasm, IPMN (low grade) 3 (2) 1 (1) – –
malignant Ductal adenocarcinomas n= 143 n = 135 (26)
PDAC 134 (78) 128 (26) 17 (13–22) –
Adenosquamous carcinoma 5 (3) 4 (0) 13 (3–17) –
Anaplastic undifferentiated carcinoma 4 (2) 3 (0) 3 (2–4) –
Carcinomas: rare cases n= 16 n = 15 (11)
Acinar cell carcinoma 2 (1) 2 (2) – –
Microcystic tubulopapillary adenocarcinoma 2 (1) 2 (1) – –
Intraductal papillary mucinous neoplasm, IPMN (invasive
carcinoma)
9 (5) 8 (5) 39 (6 –n.c{) –
SPN/Frantz’s tumor 2 (1) 2 (2) – –
Cystadenocarcinoma 1 (1) 1 (1) – –
ampullary region Carcinoma of ampulla Vateri 4 (2) 3 (2) – –
Tumor location Pancreatic head 111 (66) 108 (23) 17 (13–22) 0.79
Pancreatic body 19 (11) 15 (4) 22 (5–32)
Pancreatic tail 20 (11) 19 (8) 19 (8–n.c{)
Overlapping sites 13 (8) 11 (6) 14 (6–n.c{)
Ampulla Vateri 4 (2) 3 (2) –
TNM status Tis (T0) 3 (2) 3 (3) . 0.12
T1 3 (2) 3 (2) .
T2 2 (1) 2 (0) 30.5 (26–35)
T3 130 (76) 122 (28) 18 (14–22)
T4 19 (11) 17 (4) 12 (9–19)
no status 14 (8) 12 (4)
N0 31 (18) 30 (12) 22 (14–32) 0.32
N1 128 (75) 119 (27) 17 (13–22)
no status 12 (7) 10 (6)
M0 141 (82) 134 (36) 18 (14–23) 0.25
M1 18 (11) 15 (3) 14.5 (9–27)
no status 12 (7) 10 (6)
Grade G1 7 (4) 6 (1) 24 (5–44) , 0.0001
G2 88 (51) 85 (20) 19 (16–24)
G3 57 (33) 53 (13) 13 (9–19)
no status 15 (9) 13 (11)
Anaplastic type 4 (2) 3 (0) 2.5 (2–3)
* Logrank P-value for the differences in survival.
{ Median survival upper limit not calculable due to insufficient number of events.
doi:10.1371/journal.pone.0060870.t001
Somatic Mutations in Pancreatic Cancer
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Months (95% CI) P Hazard ratio (HR)* 95% CI
KRAS Wt 31 13 30 (13–44) 1.00 (reference)
KRAS mutants 119 24 17 (13–21) 0.05 1.87 0.99–3.51
KRAS: G12D (GAT) 70 12 16 (11–23) 0.05 1.99 1.02–3.90
KRAS: G12R (CGT) 22 5 18 (13–31) 0.93 1.04 0.39–2.75
KRAS: G12V (GTT/GTC) 20 5 16 (11–19) 0.09 2.27 0.90–5.82
KRAS: Q61H (CAC) 3 0 6 (4–35) 0.01 59.56 2.79–1272.33
K-ras: others 3 2 – 0.02 231.44 2.27–23560.74
CDKN2A Wt 112 30 19 (16–24) 1.00 (reference)
CDKN2A mutants 38 7 13.5 (9–18) 0.07 1.55 0.97–2.48
KRAS + CDKN2A wt 24 11 30 (13–44) 1.00 (reference)
KRAS + CDKN2A mutants 31 5 13(7–18) 0.01 2.77 1.23–6.23
* Hazard ratio and corresponding P-value for effect of mutations on survival calculated after adjusting with gender, age, TNM status, tumor differentiation grade and
histology.
doi:10.1371/journal.pone.0060870.t002
Figure 1. Kaplan-Meier survival curves showing difference in overall survival in PDAC patients with and without mutations. (A)
Median survival of patients with any KRAS mutations was 17 months against 30 months for patients without mutations in the gene. (B) Median
survival of patients with KRAS codon 12 GGT.GAT (G12D) mutations was 16 months against 30 months for patients without any mutation in KRAS.
(C) Median survival of patients with concomitant alterations in KRAS and CDKN2A genes was 13.5 months against 22 months for patients without any
alterations in both KRAS and CDKN2A.
doi:10.1371/journal.pone.0060870.g001
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The ADM were purported to be the originating lesions for PDAC
in mouse models [20]. Analysis of human ADM lesions showed
that KRAS mutations existed only in the lesions associated with
PanIN; the isolated ADM lesions were devoid of any KRAS
mutation, with possible involvement of two distinct mechanisms,
with and without KRAS mutations [19]. Those observations
indicate that the presence of a KRAS mutation may not be
essential for human PDAC progression and other low frequency
gene mutations could trigger alternate pathways. The pancreatic
genome sequencing of 20,661 genes from 24 tumors identified
other low frequency gene mutations [21]. A recent study reported
occurrence of 3–4 driver mutations in the KRAS, CDKN2A, TP53
and SMAD4 genes in about 30% of pancreatic tumors [15].
The codons 12, 13 and 61 of KRAS gene are part of the
conserved ‘G-domain’ (residues 1–165) required for signal
transduction. Tumor malignancy depends not on the presence of
a KRAS mutation but on the molecular configuration and
constituent mutation type [22]. Our data in this study showed
that presence of any KRAS mutation in pancreatic tumors was
associated with reduced survival time. Further analysis showed
that the association was significant only for G12D sub-type of
KRAS mutation. Lack of statistical power owing to low frequency
of other mutation types likely precluded observation of the effect
on survival. While our data being concordant with the paradigm of
distribution of KRAS mutations, we clearly showed that patients, in
particular, those harboring G12D mutation in tumors were at a 2-
fold increased risk of death compared to those without any KRAS
mutation. In an experimental study, the human cell lines with
KRAS mutations were classified into KRAS dependent and
independent. The ‘classical’ PDAC categorized as KRAS depen-
dent were shown to be potentially amenable to the directed
therapy [2,23]. The importance such studies is underlined by the
fact that mutational status in metastatic colorectal cancer is
already an approved clinical tool for treatment with epidermal
growth factor receptor monoclonal antibodies, cetuximab or
panitumumab; as mutant KRAS has been established as a predictor
of resistance to the treatment [24,25].
The association between pancreatic cancer patient survival and
specific sub-types of KRAS mutations could also be due to varying
abilities to alter the RAS protein. KRAS mutations at codon 12, in
general, have been shown to increase resistance to apoptosis and
activate AKT/protein kinase B pathway [22]. In transgenic mice,
the pancreas-specific and reversible expression of inducible KRAS
G12D mutant was shown not only to initiate neoplastic lesions but
was also involved in tumor maintenance [26]. In genetically
engineered mice G12D mutant KRAS is reported to promote
widespread colonic epithelia hyperplasia and neoplasia [27]. To
best of our knowledge, this is the first report showing a clear
association between KRAS mutation subtypes and survival. Our
previous report on paraffin embedded tumors did not show any
association between the presence of KRAS mutations and patient
survival; however, there was difference in survival between the
patients with different mutation types [14]. Lack of KRAS
mutational status as predictive of survival was also reported in
an earlier trial study of Gemctabine and Erlotinib therapy in
patients with advanced pancreatic cancer [28]. KRAS mutations in
the surgically negative resected margins have also been shown to
be associated with clinical cancer recurrence, aggressive tumor
biology and poor survival [29]. Similarly, detection of KRAS
mutations in retroperitoneal margins, in the patients with
complete pancreatectomy also showed poor prognosis [29].
The other gene that has been consistently reported to carry high
frequency of somatic mutation in pancreatic cancers is CDKN2A
[30]. The deletion/mutation frequency of CDKN2A in the present
study was in agreement with that reported in the COSMIC
database [31]. A mouse model with a conditional knock-in and
knock-out of KrasG12D and Ink4a/Arf showed enhanced progression
of pre-malignant lesions to PDAC [32,33]. In this study we found
that the subset of patients with concomitant KRAS and CDKN2A
aberrations were at 2.5-fold higher risk of death than patients
without any alterations in the two genes. In a previous study it was
shown that 1–2 mutations in pancreatic tumors showed a median
survival of 23 months compared to 13 months in our present study
[15]. The difference in median survival can be, possibly, attributed
to the fact that 149 out of 159 patients in our study had stage III
and IV tumors. Mice models have shown that survival times were
dependent on genetic aberrations accompanying a KRAS mutation
[34,35]. Similar results were reported in a study on KRAS
mutations together with loss of heterozygosity on different
chromosomal positions [29].
In conclusion, our results show that mutations in KRAS are
frequent but not universal in pancreatic tumors and the presence
of KRAS mutations in general, and G12D transformation in
particular, were indicative of association with poor survival. Our





Months (95% CI) P Hazard ratio (HR)* 95% CI
KRAS Wt 21 7 30 (12–44) 1.00 (reference)
KRAS mutants 107 19 17 (13–21) 0.03 2.19 1.09–4.42
KRAS G12D (GAT) 60 9 16 (11–23) 0.02 2.42 1.14–2.67
KRAS: G12R (CGT) 22 5 18 (13–31) 0.94 1.04 0.39–2.73
KRAS: G12V (GTT/GTC) 20 4 16 (8–19) 0.08 2.30 2.36–992.70
KRAS: Q61H (CAC) 3 0 6 (4–35) 0.01 48.43 0.70–544.44
K-ras: others 2 1 17 (–) 0.03 126.13 1.42–11221.60
CDKN2A Wt 98 22 19 (14–24) 1.00 (reference)
CDKN2A mutants 30 4 13.5 (9–18) 0.06 1.60 0.99–2.60
KRAS + CDKN2A wt 17 6 22 (12–35) 1.00 (reference)
KRAS + CDKN2A mutants 26 3 13.5 (8–18) 0.01 3.07 1.33–7.10
* Hazard ratio and corresponding P-value for effect of mutations on survival calculated after adjusting with gender, age, TNM status, and tumor differentiation grade.
doi:10.1371/journal.pone.0060870.t003
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results also showed that concomitant occurrence of KRAS
mutations and aberrations in CDKN2A resulted in a sub-group of
patients with lowest survival. Our data from this study is suggestive
for a case for the prognostic classification of pancreatic cancer
patients based on mutational status of KRAS and CDKN2A.
However, the results need independent confirmation in additional
studies with definite statistical confidence.
Materials and Methods
Ethics Statement
For all samples analyzed, written informed consent was
obtained from the patients. The study was approved by the local
ethics committee of the University of Heidelberg.
Study population
Tumor tissues were collected from pancreatic cancer patients
during surgery between January 2002 and September 2009, snap-
frozen in liquid nitrogen directly after resection and subsequently
stored at 280 uC. A total of 171 tumor tissues, that contained at
least 10% tumor by H&E staining were analyzed in the present
study. The clinical and histopathological characteristics of the
patients are given in Table 1. The cell lines A549, SW1116,
SW620, HS766T, MiaPaCa and LoVo were commercially
obtained from American Type Culture collection (ATCC) [36,37].
Histopathological assessment of cellular composition of
tissue biopsies
Three different tissue sections were selected randomly for
hematoxylin and eosin (H&E) staining and histological validation.
Slides were scanned with the ScanScope GL System (Aperio
Technologies, Vista, CA, USA) and visualized using the Image-
Scope Software. For each tissue sample, three pathologists
evaluated independently the histology and percentage of normal,
tumor and stroma cells (Figure S1). Only samples with more than
10% tumor cells were pursued further.
Genomic DNA extraction
Frozen pancreatic tissue samples were individually cut into
20 mm thick slices with a cryotome Leica CM 1850 UV at
234 uC. The tissue slices were covered with liquid nitrogen and
gently ground by three turns with a micropestle made of
polypropylene (Eppendorf, Hamburg, Germany) that fitted into
2 ml Eppendorf tubes. DNA from tissue slices and from cell lines
was extracted using the AllPrep Isolation Kit (Qiagen, Hilden,
Germany). DNA from cell lines with known KRAS mutations in
codon 12, 13 and 61 were used as controls that included, A549 cell
line with G12S (GGT.AGT) mutation; MiaPaCa, G12C
(GGT.TGT); SW 1116, G12A (GGT.GCT); SW 620 G12V
(GGT.GTT); LS-174, G12D (GGT.GAT); LoVo, G13D
(GGC.GAC); HS 766T, Q61H (CAA.CAC). DNA samples
from healthy controls were included as negative control.
PCR, single strand conformation polymorphism (SSCP)
and sequencing
PCR was carried out in 10 ml volume reactions using 10 ng of
genomic DNA, 2 mM MgCl2, 0.11 mM each dNTP, 1 mCi
[a-32P] dCTP, 0.2 mM each gene specific primer (Table S1), and
0.3 U Genaxxon Hot-start polymerase. The reactions were carried
out in 35 cycles. Electrophoresis of the amplified fragments for
SSCP was carried out on non-denaturing 0.5x MDE PAGE gels
under at least 4 different conditions (Table S1). Each experiment
was repeated twice and only when results were reproducible,
shifted bands due to mutations were subjected to sequencing. The
sequencing was carried out using a BigDye Terminator Cycle
sequencing kit (Applied Biosystems). Amplified PCR product was
treated with ExoSapIT (Amersham Biosciences, Uppsala, Sweden)
and sequencing reactions were carried out in 10 ml reaction
volumes using forward and reverse primers separately. The
reaction products were analyzed on an ABI prism 3100 Genetic
analyzer (Applied Biosystems).
Multiplex ligation-based probe amplification (MLPA)
MLPA was used to detect homozygous deletions at the CDKN2A
locus using the MLPA ME024A kit (MRC-Holland, Amsterdam,
The Netherlands) which contained 30 probes mapping chromo-
some 9p21 and 9p22, 13 reference probes and 9 internal controls.
Reference probes were located in genomic regions with low
frequency copy number changes. The hybridization and ligations
were carried out as per instructions and fragment analysis was
performed on an ABIPRISM 3130xl capillary sequencer. The
data were visualized using peak scanner v1.0 software and the
exported data was analyzed with Coffalyser software v8 (MRC-
Holland, Amsterdam, the Netherlands). Calculation of signal
ratios was carried out as described by Mistry et al. [38]. Stringent
criteria were adopted for data analysis using Coffalyser software
and experiments were repeated twice for reproducibility.
Statistical analyses
Of 171 tumors that were analyzed for mutations, 163 were
malignant and 8 non-malignant tumors. Of the 163 patients with
malignant tumors, survival data were available for 153 patients, of
whom 150 patients had malignant tumors of pancreatic origin
including ductal adenocarcinomas (n = 135) and rare carcinomas
(n = 15). The rest (n = 3) were carcinoma of ampulla of Vater
(Table 1). The Kaplan–Meier method was employed to determine
the cumulative survival curves using time period (in months)
between date of operation and the date of death. Differences
between the groups were analyzed by the log-rank test. Univariate
and multivariate Cox regression analyses were used to determine
proportional hazard ratios. For multivariate analysis variables
included were gender, age at surgery, TNM status, tumor
differentiation grade and histological status of tumors. All
statistical analyses were carried out by using SASH version 9.2
(SAS Institute Inc., Cary, NC).
Supporting Information
Figure S1 Histomorphological examination of pancre-
atic tumor tissue sections with Hematoxylin and Eosin
stains. Representative photomicrographs of three sections with
low, medium and high tumor contents are shown.
(TIF)
Figure S2 Representative SSCP of KRAS codon 12 and
codon 61 in pancreatic tumors. (A) The lanes 1–4 contain
amplified fragments of exon 2 (codon 12) and lanes 5–6 contain
amplified fragments of exon 3 (codon 61) from tumor DNA
samples. The shifted bands seen in lane 1 contain GGT.GAT
(G12D) mutation, lane 2 contains GGT.CGT (G12R), lane 3
contains GGT.GTT (G12V) mutation and lane 4 contains tumor
DNA without mutation in exon 2. The shifted bands in lane 5
contain CAA.CAC (Q61H) mutation and lane 6 contains tumor
DNA without mutation in exon 3. (B) Sequence analysis of a part
of exon 2 of KRAS gene (coding strand) with GGT.GAT (G12D)
mutation. (C) A part of exon 2 sequence showing GGT.CGT
(G12R) mutation. (D) A part of exon 2 sequence showing
GGT.GTT (G12V) mutation. (E) A part of the exon 2 showing
Somatic Mutations in Pancreatic Cancer
PLOS ONE | www.plosone.org 6 April 2013 | Volume 8 | Issue 4 | e60870
wild type sequence at codon 12 and codon of KRAS. (F) A part of
exon 3 sequence showing CAA.CAC (Q61H) mutation. (G) A
part of the exon 3 showing the wild type sequence at codon 61 of
KRAS.
(TIF)
Figure S3 Kaplan-Meier survival curves showing differ-
ence in overall survival in exocrine cancer patients with
and without mutations. (A) Median survival of patients with
KRAS mutations was 17 months against 30 months for patients
without mutations in the gene. (B) Median survival of patients with
KRAS codon 12 GGT.GAT (G12D) mutations was 16 months
against 30 months for patients without any mutation in KRAS. (C)
Median survival of patients with concomitant alterations in KRAS
and CDKN2A genes was 13 months against 30 months for patients
without any alterations in both KRAS and CDKN2A.
(TIF)
Table S1 Primer sequences and SSCP conditions for detection
of mutations in the KRAS and CDKN2A genes.
(DOC)
Table S2 Mutation frequency by clinic pathology and effect on
survival of pancreatic cancer patients.
(DOC)
Table S3 Clinico-pathological details and tumor mutational
status of all pancreatic cancer patients.
(DOC)
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